Zhejiang Ausun Pharmaceutical (603229.SH): The collaborative product Imatinib Mesylate Tablets have obtained overseas marketing approval.

Zhejiang Ausun Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's wholly-owned subsidiary Eurogenerics has received approval from the Belgian Federal Agency for Medicines and Health Products to market Imatinib Mesylate tablets. The announcement states that Imatinib Mesylate tablets are the world's first molecularly targeted anti-tumor drug, used to treat patients in the chronic phase of chronic myeloid leukemia (CML) who have failed treatment with interferon-alpha, patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). Its active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively suppresses the Philadelphia chromosome gene, inhibiting the phosphorylation reaction and the loss of chromosome function, thereby inhibiting abnormal white blood cell proliferation. It also binds to the active site of tyrosine kinase and blocks its activity.